针对PI3K异形p110δ的药物的功能影响和分子结合方式
Floyd Hassenrück1,2,3, Maria Farina-Morillas1,2,3, Lars Neumann1,2,3
1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, Cologne, Germany.
Communications biology
|June 5, 2023
概括
新的PI3K抑制剂 (PI3Ki) 针对B细胞癌中的p110δ显示出不同的有效性. 一个特定的突变 (I777M) 赋予了对某些PI3Ki的耐药性,影响了更好的癌症治疗药物设计.
科学领域:
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
- 癌症研究 癌症研究
背景情况:
- 酸3-酶 (PI3K) 抑制剂针对p110δ异型是治疗B细胞恶性瘤的关键.
- 了解耐药机制对于开发有效的PI3K抑制剂 (PI3Ki) 至关重要.
研究的目的:
- 评估各种PI3Ki化学型的功效,同型选择性和分子相互作用.
- 研究一种特定的p110δ突变 (I777M) 对PI3Ki疗效和耐药性的影响.
- 为未来PI3Ki药物设计提供结构性见解.
主要方法:
- 产生表达野生型或突变型p110δ的同源细胞系.
- 使用基于细胞的测定 (例如,AKT酸化,细胞活力) 评估PI3Ki功效和异型选择性.
- 模拟分子动力学以分析PI3Ki结合和抵抗机制.
主要成果:
- 通过保持酶活性和细胞活力,p110δ I777M突变赋予了对idelalisib的耐药性.
- 这种阻力影响p110δ选择性PI3Ki比多目标PI3Ki更大,使分子形状产生差异.
- 分子动力学模拟显示,I777M破坏了结合性灵活性,这对于结合某些PI3Ki (例如,idelalisib,ZSTK474) 至关重要,而不是其他 (例如,copanlisib).
结论:
- 当前PI3Ki的比较表征揭示了对p110δ突变的差异性疗效.
- I777M替代作为理解PI3Ki电阻的一个模型.
- 获得的结构洞察力可以指导下一代PI3Ki用于B细胞恶性瘤的合理设计.
相关概念视频
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Principles of Drug Action
6.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.2K
Phosphoinositides and PIPs
8.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K
Factors Affecting Protein-Drug Binding: Drug Interactions
208
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
208
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K


